Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 known ✓ | P35372 | 3/20 | 0.45 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.34 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.34 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.34 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MC4R | P32245 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8020175 | 0.99 | OPRM1 (0.46) | OPRM1CXCL8RORCTP53CASP1 | |
| SCHEMBL7055718 | 0.99 | OPRM1 (0.46) | OPRM1CXCL8RORCTP53CASP1 | |
| Hydrochloric Acid SCHEMBL28361730 | 0.87 | OPRM1 (0.42) | OPRM1RORCCASP1NR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL1159843 | 0.87 | OPRM1 (0.42) | OPRM1RORCCASP1NR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL1159973 | 0.87 | OPRM1 (0.42) | OPRM1RORCCASP1NR1H2NR1H3 | |
| SCHEMBL1160304 | 0.85 | OPRM1 (0.43) | OPRM1RORCCASP1NR1H2NR1H3 | |
| SCHEMBL1417521 | 0.85 | OPRM1 (0.43) | OPRM1RORCCASP1NR1H2NR1H3 | |
| Hydrochloric Acid SCHEMBL28361713 | 0.83 | OPRM1 (0.48) | OPRM1TRPM8 | |
| Hydrochloric Acid SCHEMBL1419666 | 0.82 | OPRM1 (0.37) | OPRM1RORCCASP1TRPM8ALDH1A1 | |
| SCHEMBL1609792 | 0.82 | OPRM1 (0.38) | OPRM1RORCTP53CASP1TRPM8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103435631-B | The preparation method of I-type clopidogrel hydrogen sulfate | SICHUAN EMEISHAN PHARMACEUTICAL CO., LTD. (CN) | 2015-08-26 | — | — | CN | claimed |
| CN-110776519-B | Preparation method of clopidogrel hydrogen sulfate crystal form II | 湖南迪诺制药股份有限公司 | 2020-05-26 | — | — | CN | disclosed |
| CN-110776519-A | Preparation method of clopidogrel hydrogen sulfate crystal form II | 湖南迪诺制药股份有限公司 | 2020-02-11 | — | — | CN | disclosed |
| CN-103435631-B | The preparation method of I-type clopidogrel hydrogen sulfate | SICHUAN EMEISHAN PHARMACEUTICAL CO., LTD. (CN) | 2015-08-26 | — | — | CN | disclosed |
| CN-103435631-B | The preparation method of I-type clopidogrel hydrogen sulfate | SICHUAN EMEISHAN PHARMACEUTICAL CO., LTD. (CN) | 2015-08-26 | — | — | CN | disclosed |
| US-7446200-B2 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | USV, LTD. (IN) | 2008-11-04 | — | — | US | disclosed |
| US-20070191609-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL BISULPHATE FORM-1 | LEE PHARMA LIMITED (IN) | 2007-08-16 | — | — | US | disclosed |
| US-20060074242-A1 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | USV LIMITED (IN) | 2006-04-06 | — | — | US | disclosed |
| US-6080875-A | REACTING A THIENYLGLYCIDIC DERIVATIVE WITH A PHENYLGLYCINE ESTER IN THE PRESENCE OF AN ALKALI METAL BOROHYDRIDE, DECYCLIZATION; PREPARING DRUGS FOR TREATING ANTI-PLATELET AGGREGATION AND ANTITHROMBOTIC ACTIVITIES | SANOFI-SYNTHELABO (FR) | 2000-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060074242-A1 | Rapid resolution process of clopidogrel base and a process for preparation of clopidogrel bisulfate polymorph-form I | SRR, P2RY11, CYP2C19 | OPRM1 1422/4885CXCL8 3535/4885RORC 995/4885 |
| US-20070191609-A1 | PROCESS FOR PREPARATION OF CLOPIDOGREL BISULPHATE FORM-1 | SULT1A1, SF1, ADH1C | OPRM1 1805/4885CXCL8 2583/4885RORC 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.